Evidence map›Paper›PMID 38458016›Full record

Trial reportJournal of psychosomatic research2024

An open trial of biofeedback for long COVID.

Natacha D Emerson, Helen Lavretsky, William Q Pittman, Nisha Viswanathan, Prabha Siddarth

Registry-linked trialAbstract readClinical Trial
In one paragraph

Trial report in Journal of psychosomatic research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05120648 (Effects of Biofeedback on Somatic Symptoms, Psychological Adjustment and Health Status of UCLA Patients), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05120648 completednot on this map

Effects of Biofeedback on Somatic Symptoms, Psychological Adjustment and Health Status of UCLA Patients

TypeobservationalSponsorUniversity of California, Los AngelesRan2021 to 2024Enrolled20ConditionsSomatic SymptomArmsBiofeedback
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Natacha D EmersonUCLA Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine, United States. Electronic address: NDEmerson@mednet.ucla.edu.
Helen LavretskyUCLA Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine, United States.
William Q PittmanUCLA Department of Medicine, David Geffen School of Medicine, United States.
Nisha ViswanathanUCLA Department of Medicine, David Geffen School of Medicine, United States.
Prabha SiddarthUCLA Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine, United States.
Neurobehavioral Systems · USOlive View-UCLA Medical Center · US

Funding

4/5 Neurocognitive and neuroimaging biomarkers: predicting progression towards dementia in late-life depressionR01MH114981 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LAVRETSKY, HELEN, NARR, KATHERINE L · 2017 to 2021
$1.8M
Mentoring and Research in Translational Science of Integrative MedicineK24AT009198 · NCCIH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Helen Lavretsky · 2016 to 2026
$1.4M
NCCIH NIH HHS K24 AT009198NIMH NIH HHS R01 MH114981
6 · The paper itself

Abstract

objectiveBiofeedback is a therapeutic treatment model that teaches self-regulation of autonomic functions to alleviate stress-related symptoms. "Long COVID" refers to chronic physical and cognitive sequelae post-SARS-CoV-2 infection. This study examined the efficacy of a six-week intervention, consisting of weekly one-hour sessions combining heart rate variability and temperature biofeedback, for alleviating mood symptoms, somatic symptoms and sleep disturbance of patients diagnosed with long COVID.

methodsData were collected from 20 adult participants aged 22-63 (M

resultsParticipants self-reported significant improvements in somatic, anxiety, and depressive symptoms, sleep quality, quality of life, and number of "bad days" immediately after the intervention and three months later (Cohen's d effect size (ES) = 1.09-0.46). Reduced number of medical doctor visits (ES = 0.85) and prescription drug use over the last month (odds ratio = 0.33), as well as improved emotional wellbeing (ES = 0.97) were observed at the three-month time point only.

conclusionResults suggest that this short, readily scalable intervention can be potentially efficacious in alleviating symptoms of long COVID. Despite notable improvements, the major limitation of this study is its lack of control group. While a randomized trial merits study, biofeedback appears to be a brief, effective, non-invasive, and low-cost treatment option for patients with chronic somatic symptoms secondary to SARS-CoV-2 infection. CLINICALTRIALS: govID: NCT05120648.

Indexed as

COVID-19AdultBiofeedback, PsychologyHumansPost-Acute COVID-19 SyndromeQuality of LifeSARS-CoV-2BiofeedbackDysautonomiaHeart rate variabilityLong COVIDPost-acute sequelae of SARS COV-2 infection (PASC)

Identifiers

PMID38458016
PMCPMC13322610
OpenAlexW4392112423

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.